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Nobiletin suppresses cell viability through AKT
Pathways in PC-3 and DU-145 prostate cancer cells
Jianchu Chen1,2, Ashley Creed2, Allen Y Chen3, Haizhi Huang1,2, Zhaoliang Li2, Gary O Rankin4, Xingqian Ye1,
Guihua Xu1 and Yi Charlie Chen2*

Abstract
Background: Nobiletin is a non-toxic dietary flavonoid that possesses anti-cancer properties. Nobiletin has been
reported to reduce the risk of prostate cancer, but the mechanism is not well understood. In this study, we
investigated the effects of nobiletin in prostate cancer cell lines PC-3 and DU-145.
Methods: Nobiletin was isolated from a polymethoxy flavonoid mixture using HPLC, cell viability was analyzed with
MTS-based assays. Protein expression was examined by ELISA and western blotting. Gene expression was examined by
luciferase assay. And the pathways were examined by manipulating genetic components with plasmid transfection.
Results: Data showed that nobiletin decreased cell viability in both prostate cell lines, with a greater reduction
in viability in PC-3 cells. HIF-1α expression and AKT phosphorylation were decreased in both cell lines. The VEGF
expression was inhibited in PC-3 but not DU-145 cells. cMyc expression was decreased in DU-145 cells. Nobiletin
down-regulated NF-κB (p50) expression in nuclei of DU145 cells but not whole cells. It also suppressed NF-κB
expression in both whole cells and nuclei of PC-3 cells. Increasing HIF-1α levels reversed nobiletin’s inhibitory
effects on VEGF expression, and up-regulating AKT levels reversed its inhibitory effects on HIF-1α expression.
We speculate that AKT influences cell viability probably by its effect on NF-κB in both prostate cells. The effect
of nobiletin on VEGF expression in PC-3 cell lines was through the AKT/HIF-1α pathway.
Conclusion: Taken together, our results show that nobiletin suppresses cell viability through AKT pathways, with a
more profound effect against the more metastatic PC-3 line. Due to this enhanced action against a more malignant
cell type, nobiletin may be used to improve prostate cancer survival rates.
Keywords: Nobiletin, Prostate cancer, VEGF, NF-κB, HIF-1α, cMyc

Background
Prostate cancer is the second most common cancer in
the United States, as well as, the second leading cause
of mortality among males in the western world [1].
Approximately 25% of all newly diagnosed cancers in
American men are prostate cancer [2]. Studies relating
lifestyle to the risk of prostate cancer have become
more prevalent in recent years due the escalating number of prostate cancer cases over the past decade [1].
Nevertheless, the etiology of prostate cancer is still
uncertain because no specific carcinogen is known to
cause this disease [3]. Research has found that certain
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risk factors, such as advancing age, African American
ethnicity, and a positive family history, are associated
with the likelihood of developing prostate cancer [4].
However, research has also shown that prostate cancer
is not solely due to genetic factors, but is also related to
lifestyle, diet, and environmental factors [4-6]. It is now
believed that 90-95% of all cancers are caused by lifestyle [7]. This observation has encouraged researchers
to identify dietary components, such as flavonoids like
nobiletin, which may have anticancer properties.
It has been suggested that dietary intake of natural
products rich in citrus flavonoids can play an important
role in chemoprevention [8,9]. Flavonoids are phytochemicals found in fruits, vegetables, teas, and wines.
Flavonoids display anti-carcinogenic characteristics in vitro
and might be able to decrease cancer risk by changing
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levels of sex hormones, preventing oxidation or inflammation, diminishing angiogenesis or cell proliferation,
or stimulating apoptosis [10]. There are more than 400
flavonoids found in our food supply; however, in this
research we focused our attention on nobiletin [11].
Nobiletin is an O-methylated flavonoid found in citrus
peels with an empirical formula of C21H22O8 and molecular weight of 402.39 [12]. An inverse relationship has
been identified between nobiletin and cancer risk, which
is likely due to nobiletin’s anticancer, antiviral, and antiinflammatory activities [13,14]. More specifically, recent
findings have identified nobiletin as a cell differentiation
modulator. Cell differentiation is a crucial step in angiogenesis and therefore could affect tumor growth and
metastasis which both depend on angiogenesis [15].
Research has also shown that a diet high in flavonoids
reduced oxidative damage to deoxyribonucleic acid (DNA),
blocking a significant step in the onset of some types of
cancers [16]. These findings support the proposition that
nobiletin is functionally unique and could be a possible
chemopreventive agent in inflammation-associated tumorigenesis [17].
Currently, metastatic prostate cancer is incurable and
ultimately claims the life of patients [18,19]. An important factor in the relative seriousness of prostate cancer is
the invasiveness of the constituent tumor cells causing
metastasis [19]. Nobiletin has been reported to reduce
the risk of prostate cancer, but the mechanism is not well
understood. Therefore we studied the effects of nobiletin
in prostate cancer cell lines PC-3 and DU-145. The
pathways that affect the viability and VEGF expression
of these cell lines have also been investigated in this
paper. DU-145 and PC-3 are prostate cancer cell lines
with moderate and high metastatic potential, respectively
[20]. In the present study, we isolated nobiletin from a
polymethoxy flavonoid mixture. Then we investigated the
effect of nobiletin on cell viability in prostate cancer cell
lines PC-3 and DU-145 and also performed western blotting and ELISA to identify changes in protein expression.
Moreover, we examined the VEGF changes through transfection of AKT and HIF-1α plasmids in luciferase assays.

Methods
Cell culture and treatment

PC-3 cells were cultured in F-12K medium (ATCC,
Manassas, VA) supplemented with 10% US-qualified
fetal bovine serum (FBS) (Invitrogen, Grand Island,
NY). DU-145 cells were cultured in Eagle’s minimum
essential medium (ATCC, Manassas, VA) supplemented
with 10% US-qualified fetal bovine serum. All cells were
cultured in a cell culture incubator with 5% CO2 at 37°C.
Nobiletin was dissolved in dimethyl sulfoxide (DMSO) to
make stock solutions of 100 mM and equal amount of
DMSO was included in controls for every experiment.
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Cell proliferation assay

Effects of nobiletin on prostate cancer cells (PC-3 and
DU-145) viability were colorimetrically determined with
a “Cell Titer 96 Aqueous One Solution Cell Proliferation
Assay” kit from Promega (Madison, WI). Cells (5 × 103/
well) were seeded into 96-well plates and incubated for
16 h before being treated with 0 to 160 μg/ml nobiletin
in triplicates for 24 h with DMSO as solvent control.
After removing the medium, cells were washed with
phosphate buffered saline (PBS), and then 100μL Aqueous
One Reagent dilute solution (80 μL PBS +20 μL Aqueous
One Reagent) was added to each well. Cells were incubated
at 37°C for 1.5 h and measured for optical density (OD)
values at 490 nm. Cell viability was expressed as a percentage of control from three independent experiments.
ELISA for VEGF

Secreted vascular endothelial growth factor (VEGF) protein
levels were analyzed by sandwich enzyme-linked immunosorbent assay (ELISA) with a Quantikine Human VEGF
Immunoassay Kit from R&D Systems (Minneapolis, MN)
targeting VEGF in cell culture supernates. Cells (104/well)
were seeded into 96-well plates and incubated for 16 h
before being treated with 0 to 160 μg/ml nobiletin in triplicates for 24 h with DMSO as solvent control. Culture
supernates were collected for VEGF assay. VEGF levels
were determined following the manufacturer's instructions.
A total of 3 independent experiments, each in triplicates,
were assayed, and the mean VEGF protein level from each
duplicate was used for statistical analysis.
Western blot

Prostate cancer cells (106) were seeded in 60-mm dishes
and incubated for 16 h before treatment with nobiletin
for 24 h. After washing with PBS, cells were harvested with
100 μL Mammalian Protein Extraction Reagent including
1 μL Halt Protease, 1 μL Phosphatase Inhibitor and 2 μL
EDTA (Thermo Scientific, Rockford, IL). Cells were then
frozen at -80°C for 30 min, melted, centrifuged at 12,000 g
at 4°C for 10 min, and collected in aqueous phase for
measurement. Nuclear protein was extracted by NE-PER™
Nuclear and Cytoplasmic Extraction Reagents (Thermo
Scientific, Rockford, IL). Total protein levels were assayed
with a BCA Protein Assay Kit (Pierce, Rockford, IL), and
lysates were separated by 10% SDS-PAGE and blotted
into nitrocellulose membrane. For immune detection,
antibodies against HIF-1α, NF-κB (p50), PTEN, cMyc,
GAPDH, p-AKT, total AKT (Santa Cruz Biotechnology,
Santa Cruz, CA) and PCNA (Cell Signaling Technology,
Boston, MA) were applied and signals visualized with
x-ray film (Pierce Biotechnology, Rockford, IL). Protein
bands were quantitated with NIH ImageJ software, normalized to corresponding GAPDH, PCNA or total AKT
bands, and expressed as percentages of control. A total
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of three independent experiments were carried out for
statistical analysis.
Transient transfection and luciferase assay

PC-3 prostate cancer cells were seeded in 96-well plate
at 104 cells/well and incubated overnight. The cells were
then transfected with 0.05 μg VEGF (Hif-1α) luciferase
reporter, 0-0.25 μg HIF-1α (AKT) or SR-α plasmids by
0.6 μL jetPRIME reagent (VWR, West Chester, PA) for 4
hours, followed by 16 hour treatment with 0 or 40 μM
nobiletin. The cells were harvested and analyzed for
luciferase and total protein levels, and the levels of VEGF
(HIF-1α) reporter were normalized by corresponding total
protein levels. Data represent Means ± SE from three
independent experiments.
Statistical analysis

Results were expressed as mean ± standard error of mean
(SEM). Statistical assessment was carried out with the
program system of SPSS (Version 16.0 for Windows). The
results were analyzed using one-way analysis of variance
(ANOVA) and post hoc test (2-sided Dunnett's t) to test
both overall differences and specific differences between
each treatment and control. A p value of less than 0.05
was considered significant.

Results
Isolation and identification of nobiletin

Nobiletin was prepared from a polymethoxy flavonoid
mixture, which was provided by Zhejiang Quzhou Tiansheng Plant Extraction Co. Ltd. in China, containing about
60% nobiletin and tangeretin. The polymethoxy flavonoid
mixture was dissolved in methanol-dimethyl sulfoxide (1:1)
to a concentration of 50 mg/mL. Then it was chromate
graphed with high-performance liquid chromatography
(HPLC), eluted with methanol-H2O (70:30) in 8 mL/min at
room temperature, separated into two fractions (Fractions I
and II), collected individually, and evaporated.
Fraction I and fraction II were obtained by HPLC
(Figure 1(a)). Fraction I was identified as nobiletin
by HPLC-MS (Figure 1(b)), UV-vis chromatography
(Figure 1(c)) and comparing peak time with that of
nobiletin sample from Sigma (Figure 1(d)) and previous
reports. Its purity was above 98%.
Nobiletin inhibits cell viability in prostate cancer cell lines

Cell viability steadily decreased as nobiletin concentration increased in both cell lines (Figure 2). Beginning at
a concentration of 10 μM nobiletin, PC-3 cell viability
consistently decreased from 95% to 40% at a concentration of 160 μM nobiletin (p < 0.01). Similarly, DU-145
cell viability was also inhibited with each successive
doubling of concentration. At a concentration of 10 μM
nobiletin cell viability was 92% (p < 0.05), which was
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gradually inhibited to 46% by a 160 μM nobiletin treatment (p < 0.01). An overall inhibitory effect on cell viability was observed for both cell lines, although DU-145
(IC-50 = 137 μM nobiletin) cells appear more resistant
than PC-3 cells (IC-50 = 117 μM nobiletin) to the inhibiting effect of nobiletin. It is in agreement with the cell
viability determined by WST-1 assay [21].
Nobiletin inhibits VEGF expression in prostate cancer cell
line PC-3

The levels of VEGF protein in PC-3 cell culture supernates were down-regulated to 70% at a concentration of
10 μM nobiletin (p < 0.01) and to 18% at a concentration
of 160 μM nobiletin (p < 0.01) (Figure 3). However, the
levels of VEGF protein in DU-145 cells ranged from
90-110% with no consistency with respect to nobiletin
concentration. Our study revealed that VEGF expression
was significantly (p < 0.01) reduced in PC-3 cancer cells by
nobiletin treatment.
Nobiletin inhibits HIF-1α (Hypoxia inducible factor)
protein expression in prostate cancer cell lines

HIF-1α protein levels in PC-3 cells showed intense
and consistent down-regulation by nobiletin treatment
(Figure 4). A 20 μM nobiletin treatment led to inhibition
of HIF-1α protein to 70% (p < 0.01). Higher concentrations of nobiletin resulted in greater inhibition, with
the levels of HIF-1α protein down to 48% by a 40 μM
nobiletin treatment (p < 0.05) and 10% by a 80 μM
nobiletin treatment (p < 0.01). HIF-1α protein levels in
DU-145 cells showed consistent but gradual downregulation by nobiletin treatment. DU-145 cells seem to
be much more resistant to nobiletin treatment with
down-regulation ranging from 94% at a concentration
of 20 μM nobiletin to 79% at a concentration of 80 μM
nobiletin (p < 0.05). HIF-1α expression in both cells
lines (PC-3 and DU-145) was inhibited by nobiletin
treatment, with a greater inhibition in PC-3 cells.
Nobiletin inhibits phosphorylation of AKT in prostate
cancer cell lines

P-AKT levels were down-regulated from 65% by a 20 μM
nobiletin treatment to 56% by a 80 μM nobiletin treatment
(p < 0.01) in PC-3 cells (Figure 5). In DU-145 cells, p-AKT
levels were down-regulated to 67% by a 20 μM nobiletin
treatment (p < 0.05), to 51% by a 80 μM nobiletin treatment
(p < 0.01). The percentage of down-regulation in each cell
line was similar at each treatment concentration and indicates that nobiletin could decrease AKT phosphorylation
for both PC-3 and DU-145. However, the observed downregulation seemed to subside at 40 μM nobiletin treatment,
with not much difference resulting at 80 μM nobiletin
treatment for both cell lines. Therefore, higher concentrations may not be any more beneficial.
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Figure 1 Isolation and identification of nobiletin. (a) Preparation HPLC graph of nobiletin and tangeretin. (b) HPLC-MS graph of nobiletin.
(c) UV-vis chromatography of nobiletin. (d) HPLC graph of nobiletin.
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DU-145

a

PC-3

b

Figure 2 Effect of nobiletin on viability of PC-3 and DU-145 cells. (a) DU-145 cells, (b) PC-3 cells. Cells (5.0 × 103 /well) were seeded in 96-well plates,
incubated for 16 h, and treated with nobiletin for 24 h. Cell viability was colorimetrically determined by a MTS-based method and expressed as percentages
of control. Data represents mean ± SE from 3 independent experiments. *P < 0.05 as compared to control. **P < 0.01 as compared to control.

Nobiletin inhibits cMyc expression in prostate cancer cell
line DU-145

In PC-3 cells, cMyc levels were slightly down regulated
to 93% by a 40 μM nobiletin treatment and to 90% by a
80 μM nobiletin treatment (Figure 6). The results were
very gradual, revealing that the PC-3 cells have a high level
of resistance and there was no statistical significance
among treatments. The cMyc levels in DU-145 cells were
down-regulated to 79-84% by nobiletin treatment. Therefore, nobiletin reduced cMyc expression in DU-145 cells,
but showed no evidence of inhibition in PC-3 cells.
Nobiletin inhibits NF-κB (p50) expression in nucleus of
prostate cancer cell

NF-κb (p50) expression was down-regulated in both whole
cells and nuclei of PC-3 cells when treated with nobiletin.
At the concentration of 80 μM nobiletin, its expression was
inhibited by 28% (p < 0.01) and 37% (p < 0.05) respectively
in whole cells and nuclei. In nuclei of DU145 cells, p50
expression was inhibited to 42% (p < 0.01) by a 40 μM nobiletin treatment and 10% (p < 0.01) by a 80 μM nobiletin
treatment (Figure 7). However, its expression in whole cells
was up-regulated to 103-112% with higher concentrations
of nobiletin resulting in greater promotion.

Effect of nobiletin on PTEN expression

Our study found that nobiletin had no significant effect
on PTEN expression in DU-145 cells (Figure 8). PTEN
was not expressed in PC-3 cells.
Nobiletin inhibits VEGF expression through regulating
AKT and HIF-1α gene in prostate cancer cell line PC-3

We used PC-3 cancer cells with low levels of AKT and
HIF-1α expression to test whether nobiletin affects VEGF
expression. Our study found that transfected plasmid
AKT and HIF-1α concentration-dependently reversed
nobiletin’s inhibitory effects (Figure 9). Our findings suggest that nobiletin regulates VEGF expression through
down-regulating AKT and HIF-1α in prostate cancer cells.

Discussion
Approximately 25% of all newly diagnosed cancers in
American men are prostate cancer [2]. The risk of developing prostate cancer is associated with advancing age,
African American ethnicity, and a positive family history
[4]. However, research has also shown that diet and
other lifestyle factors may influence prostate cancer risk
[4]. Studies relating lifestyle to the risk of prostate cancer

Figure 3 Effect of nobiletin on VEGF expression in PC-3 and DU-145 cells. (a) DU-145. (b) PC-3. Cells (1.0 × 104/well) were seeded into
96-well plates , incubated for 16 h, and treated with nobiletin for 24 h. Vascular endothelial growth factor (VEGF) in cellculture supernate were
analyzed with a Quantikine Human VEGF Immunoassay Kit from R&D Systems (Minneapolis, MN). Data represents mean ± SE from 3 independent
experiments. *P < 0.05 as compared to control. **P < 0.01 as compared to control.
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DU-145 GAPDH

Figure 4 Nobiletin's effects on HIF-1α expression in PC-3 and DU-145 cells. Nobiletin's effect on HIF-1α expression. PC-3 and DU-145 cells
(1.0 × 106) were seeded in 60-mm dishes, incubated overnight, and treated with nobiletin for 24 hours. Cells were harvested and analyzed by
SDS-PAGE and Western Blotting. HIF-1α protein levels were normalized by GAPDH protein levels. Data represents means ± SE from 3 independent
experiments. *P < 0.05 compared to control. **P < 0.01 compared to control.

have become more prevalent in recent years due to the
escalating number of prostate cancer cases.
It has been suggested that dietary intake of natural
products rich in flavonoids from citrus fruits may play a
role in the prevention of cancer [8]. Tangeretin, nobiletin,
hesperetin, hesperidin, naringenin, and naringin are just a
few examples of citrus flavonoids that have the potential to
be used as chemotherapeutic agents. Research has shown
that these flavonoids possess inhibition activity on certain
cancer cells' growth through various mechanisms [8].

Nobiletin(µM) 0 20 40 80
PC-3 p-AKT
PC-3 t-AKT

Nobiletin, a citrus polymethoxy flavonoid, possesses anticancer, antiviral, and anti-inflammatory activities [14].
More specifically, recent findings have identified nobiletin
as a cell differentiation modulator. Cell differentiation is a
crucial step in angiogenesis and therefore could affect
tumor growth and metastasis which both depend on
angiogenesis [15]. These findings support the proposition
that nobiletin is functionally unique and could be a possible chemopreventive agent in inflammation-associated
tumorigenesis [17].

Nobiletin(µM) 0 20 40 80
DU-145 p-AKT
DU-145 t-AKT

Figure 5 Nobiletin's effect on AKT phosphorylation in PC-3 and DU-145 cells. PC-3 and DU-145 cells (1.0 × 106) were seeded in 60-mm dishes,
incubated overnight, and treated with nobiletin for 24 hours. Cells were harvested and analyzed by SDS-PAGE and Western Blotting. P-AKT protein
levels were normalized by total AKT protein levels and expressed as percentages of control. Data represents means ± SE from 3 independent
experiments. *P < 0.05 compared to control. **P < 0.01 compared to control.
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Figure 6 Nobiletin’s effect on cMyc. PC-3 and DU-145 cells (1.0 × 106) were seeded in 60-mm dishes, incubated overnight, and treated with
nobiletin for 24 hours. Cells were harvested and analyzed by SDS-PAGE and Western Blotting. cMyc levels were normalized by GAPDH protein
levels and expressed as percentages of control. Data represents means ± SE from 3 independent experiments. *P < 0.05 compared to control.
**P < 0.01 compared to control.

We tested the effectiveness of the preventive and/or
treatment measures that nobiletin exhibits on PC-3 and
DU-145 prostate cancer cells and showed that PC-3 and
DU-145 cell viability was suppressed concentrationdependently by nobiletin treatment. Several pathways
including VEGF, HIF-1α, AKT phosphorylation, cMyc,

and NF-κB influence cell viability inhibition. In both
cell lines, nobiletin inhibited phosphorylation of AKT,
which is known to be the major signal for cell survival
and proliferation [22]. Nobiletin treatment also reduced
NF-κB (p50) expression in nuclei of both prostate cancer
cells. NF-κB activation plays many roles when it enter into

Figure 7 Nobiletin's effect on NF-κB (p50) expression. (a) Effect of nobiletin on total NF-kB expression, (b) Effect of nobiletin on nuclear
NF-kB expression. PC-3 and DU-145 cells (1.0 × 106) were seeded in 60 mm dishes, incubated overnight, and treated with nobiletin for 24 hours.
Cells were harvested and analyzed by SDS-PAGE and Western Blotting. NF-кB protein levels whole cells were normalized by GAPDH protein levels
and its protein levels of nucleus were normalized by PCNA protein levels. They were expressed as percentages of control. Data represents
means ± SE from 3 independent experiments. *P < 0.05 compared to control. **P < 0.01 compared to control.
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Figure 8 Nobiletin’s effect on PTEN expression. PC-3 and DU-145 cells (1.0 × 106) were seeded in 60-mm dishes, incubated overnight, and
treated with nobiletin for 24 hours. Cells were harvested and analyzed by SDS-PAGE and Western Blotting. PTEN protein levels were normalized by
GAPDH protein levels and expressed as percentages of control. Data represents means ± SE from 3 independent experiments. *P < 0.05 compared to
control. **P < 0.01 compared to control.

the nucleus, including initiating cellular transformation,
mediating cellular proliferation, mediating cellular invasion and angiogenesis, mediating metastasis, and linking
inflammation and cancer [23,24]. Suppression of NF-κB in
tumor samples also inhibits proliferation, causes cell cycle
arrest, and leads to apoptosis, indicating the crucial role of
NF-κB in cell proliferation and survival [25]. Some
researchers have found that the expression, activation and
translocation of NF-κB were regulated by AKT pathways
[26-28]. Our results showed that nobiletin treatment
could decrease NF-κB expression in nuclei of both cells

and AKT phosphorylation, indicating that AKT may influence cell viability by its effect on NF-κB in both prostate
cells. It was also found that HIF-1α promoter is responsive
to selective NF-κB subunits, indicating that NF-κB is a
direct modulator of HIF-1α expression [29]. VEGF is a
signal protein produced by cells related to vasculogenesis
and angiogenesis, and it is also the downstream gene of
HIF-1α. Our study revealed that VEGF expression was
significantly (p < 0.01) reduced in PC-3 cancer cells by
nobiletin treatment. HIF-1α expression in both cells
lines (PC-3 and DU-145) was also inhibited by nobiletin

Figure 9 Nobiletin inhibits VEGF expression by regulating AKT and HIF-1α gene in PC-3 cells. (a) Nobiletin inhibits VEGF expression by
regulating HIF-1 α gene, (b) Nobiletin inhibits VEGF expression by regulating AKT gene. PC-3 prostate cancer cells were seeded in 96-well plate at
10,000 cells/well and incubated overnight. The cells were then transfected with 0.05 ug VEGF (Hif-1α) luciferase reporter, 0-0.25 μg HIF-1α (AKT)
or SR-α plasmids by 0.6 μL jetPRIME reagent for 4 hours, followed by 16 hour treatment with 0 or 40 μM nobiletin. The cells were harvested and
analyzed for luciferase and total protein levels, and the levels of VEGF (Hif-1α) reporter were normalized by corresponding total protein levels.
Data represent Means ± SE from 3 independent experiments. #p < 0.05 as compared to control. ##p <0.01 as compared to control. *p <0.05
as compared to nobiletin-treated control. **p <0.01 as compared to nobiletin-treated control.
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treatment, with a greater inhibition in PC-3 cells. Furthermore, it was found that nobiletin inhibited VEGF
expression through regulating AKT/HIF-1α pathways
in prostate cancer cell line PC-3. Increasing HIF-1α
levels actually reversed nobiletin’s inhibitory effects on
VEGF expression. Similarly up-regulating AKT levels
reversed its inhibitory effects on HIF-1α expression. These
results correspond to a previous study that HIF-1α/VEGF
expression can be regulated by AKT pathways [30]. Nobiletin reduced cMyc expression in DU-145 cells, but
showed no evidence of inhibition in PC-3 cells. PTEN has
been shown to play a pivotal role in apoptosis, cell cycle
arrest, and possibly cell migration. PTEN is the most
frequently mutated gene in prostate cancer, loss of heterozygosity at 10q23 can be detected in approximately 50% of
human prostate cancers, whereas homozygous deletions
of PTEN can be detected in approximately 10% of these
cases [31]. However, nobiletin appears to lower cell
viability through a mechanism independent of PTEN,
as it does not seem to affect PTEN concentrations.
Our research indicated that nobiletin is a good candidate
for the chemoprevention of prostate cancer in humans and
could be an effective measure in inhibiting prostate cancer
cell viability. Nobiletin has the apparent ability to suppress
cell viability through multiple pathways, thus inhibiting
tumor growth. Most encouraging is its capacity to suppress
the more metastatic PC-3 cell line. Since the lethality of
a tumor links directly to its ability to spread, nobiletin
promises to increase the prostate cancer survival rate.
However, more data needs to be obtained on nobiletin’s
toxicity and tolerable dosages before it can become part
of prostate cancer prevention and/or treatment. Also,
as an in vitro model, cell culture cannot take absorption,
distribution, metabolism, and excretion of nobiletin into
consideration. Further studies in animal models and human trials are warranted to determine if physicians can
promote this natural compound toward chemoprevention
of prostate cancer cells.

Conclusion
Our research indicated that nobiletin is a good candidate
for the chemoprevention of prostate cancer in humans
and could be an effective measure in suppressing prostate cancer cell viability. For these two prostate cancer
cell lines, nobiletin has the apparent ability to suppress
cell viability concentration-dependently through multiple
pathways (VEGF, HIF-1α, AKT phosphorylation, cMyc,
and NF-κB). Because nobiletin seems to work better
against the more dangerous PC-3 cell line, nobiletin holds
real potential in improving prostate cancer outcomes.
However, more data needs to be obtained on nobiletin’s
toxicity and tolerable dosages before it can become part of
prostate cancer prevention and/or treatment. Also, as an
in vitro model, cell culture cannot take absorption,
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distribution, metabolism, and excretion of nobiletin into
consideration. Further studies in animal models and
human trials are warranted to determine if physicians can
promote this natural compound toward chemoprevention
of prostate cancer cells.
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